Catalyst Pharmaceutical Partners, Inc. Announces FDA Designation of CPP-115 as a Fast Track Development Program

CORAL GABLES, Fla., Dec. 20, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that its investigational drug, CPP-115, a novel GABA aminotransferase inhibitor, has been designated as a Fast Track development program by the FDA for the treatment of cocaine dependency.

MORE ON THIS TOPIC